Neurogene Inc Investor Event Transcript, Nov 11, 2026
Neurogene Inc. (NGNE)
NeuroGene completed dosing in the NGN-401 pivotal study and expects data in the second half of 27. It had about $360 million in cash and equivalents at quarter-end, funding operations into the first quarter of 29. AI summary
Conference Transcript - NGNE 2026-11-11
Speaker 0
All right. Thanks, everybody. Happy to be moderating this fireside chat with Rachel McMinn, founder and CEO of NeuroGene. We'll dive into a bunch more specific questions around the data so far and the pivotal study design and regulatory alignment and stuff. But maybe I'll turn it over to Rachel just to briefly give some quick opening remarks and sort of an update on where everything stands with the program.
Rachel McMinn, CEO
Yeah, thanks, Paul. Thanks for the invitation. Really happy to be here. So again, Rachel McMinn, founder and CEO of NeuroGene. We are a late-stage clinical genetic medicines company focused on developing treatments for rare, devastating neurological disorders. Our lead program is NGN 401 for the treatment of Rett syndrome, which is really just a very devastating disease, huge unmet need, somewhere between 15,000 to 20,000 people in the U.S., as well as major European markets that have this disease. And there are no treatments that, you know, really address the underlying disease course. So this is a really exciting opportunity for the community, for NeuroGene. NGN401 completed dosing of our pivotal study, and I know we'll have lots of questions on that, but we completed dosing. We announced that in early June. It's a 12-month study, so we will have data in the second half of next year. And then in terms of, you know, kind of what's going on in the overall state of the state, it's a really exciting time. We're in the process of literally transitioning into a pre-commercial, kind of commercial stage company in anticipation of a future BLA approval. So there's a lot of work going on at NeuroGene right now, both on the pre-commercial build-out, and we can talk a little bit about that, and the medical affairs team out in the field and continuing to build and grow the commercial function for pre-commercial activities. And then on the science side, just continuing to generate new data to help differentiate NGN-401, and I know we'll get to that as well. So just a really exciting time for the company, and I guess maybe two other things I should mention on the pre-commercial front is very much on track for completing PPQ before the end of the year. So this is a CMC activity, which, you know, for anyone who's in gene therapy, there's a lot of work, and our team is, you know, actively completing PPQ as we speak. So, BLA authoring has, like, already kicked off. So, we're, you know, we're really trying to get a jump on this and, you know, front load as much of the work as possible so that we can, you know, very efficiently file after top-line results in the second half of 27.
Speaker 0
Great. Maybe to start, do you want to just kind of level set and talk about the most recent data cut you saw from the Phase 1-2 study, what you've seen with durability, various milestones, things like that?
Rachel McMinn, CEO
Yeah, so as a reminder, we dosed 10 participants at a 1E15 vector genome dose. These patients ranged anywhere from four years to 18 years of age, and they had a clinical and genetic disease severity spectrum from mild, moderate, severe. All of these patients are very impaired, but in terms of the scale for Rett syndrome. So really representing the broad range of patients out there. All patients improved as assessed by the CGII, as well as gaining one or more developmental milestones. And in terms of, you know, what that looked like over time, what we saw is patients gaining milestones as early as the first three-month assessment. And the number of milestones and the breadth of milestones continue to augment at six months, nine months, 12 months, and beyond. In terms of durability, really important question, right? If you're giving a gene therapy for a disease like Rett syndrome, which is a chronic, lifelong, you know, absolutely debilitating disorder, you want to make sure that these milestones are durable. And I'm happy to report that, you know, all of our participants, once a milestone has been gained, they've been able to retain that.
Speaker 0
On the durability piece, how is that codified exactly? Are these patients, like, formally and systematically, like, re-challenged to perform tasks, or is it more, like, anecdotal at this stage where they've gained something and then it's sort of conveyed that they continue to perform that task?
Rachel McMinn, CEO
So this is really verified through an independent rater of caregiver videos or clinician-based videos in the clinic. So it's a combination of those things. But yeah, it's things that we can document.
Speaker 0
Yeah. Okay. And then as it relates to safety, so you completed dosing earlier this year in the phase three study. So maybe talk about like total number of patients and what you're seeing from a safety perspective and your level of comfort there.
Rachel McMinn, CEO
Yeah, so we dosed 25 participants in emboldened. So this is on top of the 10 participants that we talked about with phase one, two. So a total safety database of 35 participants at the 1A15 dose. While we're not making detailed safety comments, you know, on a quarter by quarter basis, it's an ongoing, you know, active registrational trial that wouldn't be appropriate. But we are, you know, what we have mentioned as, you know, as of November 8th, our earnings release that we just put out mentioned that, you know, NGN 401 continues to be well tolerated. So to the extent that, you know, folks, you know, have concerns about, you know, an earlier toxicity that had happened with a much higher dose, you know, HLH, we've, you know, reaffirmed that we've not seen anything like that. If you were to see that, that would happen, you know, very close in time to dosing. And we're well past that treatment window. So I think we're feeling very good about the tolerability profile.
Speaker 0
Maybe remind people of the statistical hurdle for success. And then how are you thinking about the actual, like, hurdle for success for you for, you know, maybe one commercially thinking that you can really kind of capitalize on this market and make a difference the way you want to? And then also from like an FDA perspective, like do you feel like, you know, you have regulatory sign-off, we'll talk about that, but do you feel like the FDA with giving you this flexible path is maybe, you know, playing for something that's a little bit more transformative than the minimum statistical bar?
Rachel McMinn, CEO
Yeah, so multiple questions in there, but let's just take a step back. So the emboldened trial is a baseline controlled study, and what that means is that these participants are actually serving as their own control. And this was really unique and special, and we were able to design this in consultation with the FDA. The primary endpoint, I alluded to it before, but just to be very clear, it's a composite endpoint of both an improvement in the Clinician Global Impression Improvement, or CGI-I, as well as a gain of one or more pre-specified, pre-determined 28 developmental milestones. And to give you a sense, because like a lot of people, it's like developmental milestones, what does that mean? You know, for folks who have kids, this might be more obvious, but, you know, being able to hold a cup and drink that, you know, unassisted, that is a developmental milestone, being able to sit unassisted or go up the stairs by yourself, being able to express yourself, you know, whether somebody is given a gesture or not, but being able to, you know, react to a command and like do what your mom actually tells you. Put your backpack over here or go eat your food. These are the kinds of things that we're looking for in the phase, sorry, in the emboldened study. So the way this works is participants come in, they have a very rigorous baseline assessment. To kind of establish what is that baseline, right? Because all of these girls are different. And one of the really strong rationales to have a baseline control is you wouldn't be able to get a homogenous like, well, everybody, you know, does this because, you know, no two rat girls are really the same. They all have slightly different, you know, levels of function. So the idea is to rigorously establish the baseline, and then from there, go in and, as you kind of alluded to before, have these pre-specified challenge tasks of like, okay, if she has no hand function at all, maybe her challenge task will be reaching out. But if she's already able to reach out, then maybe her task is to pick up a small object like a Cheerio and kind of show that she has that pincer grasp.
Speaker 0
And these capabilities are all determined at baseline. Is that right?
Rachel McMinn, CEO
Exactly. So you want to establish that to understand what are tasks that are safe to perform. And then once you do that, then it's like, okay, let's see, can Jane or Susie, as exemplars, can they do these various things? That gets recorded in a standardized video assessment. Everything is very well spelled out in a manual. And then those videos are not handled by the treating clinician at all. So this is a really important part of how do we keep this as a, you know, adequately, well-controlled, rigorous assessment. Right. So those videos then get shipped off to two central raters that are blinded, and they're blinded to everything. So they don't know that we're neurogene. They don't know that these girls have Rett syndrome. They don't know that they're testing a gene therapy. You know, obviously, this happens to be a single arm study, so they don't know whether girls are getting placebo or not placebo. And then all of the videos are mixed up. And so they're blinded at time as well.
Speaker 0
This is for the Pivotal program.
Rachel McMinn, CEO
For the Pivotal. For the Pivotal. And so the reason why I'm outlining all of this for you is that when you asked about flexibility, so there is flexibility from the FDA.
Speaker 0
But this is not your open label everybody knows.
Rachel McMinn, CEO
Yeah, this is not a big party where you're just like, hey, let's do this, and maybe we'll do it this way for this patient and that way for that patient. Everything is standardized. And as I said, it's blinded. And that's really important because it allows you to have that, you know, evidentiary body that you can then, like, once you have that data, you're going to be much more convinced that it's, quote, unquote, like, a real finding. So that's a really big piece of the milestone assessments. CGII, you really can't blind that. That is the clinician literally, like, asking the caregiver, you know, how's your daughter doing, doing the various assessments in clinic. You can't eradicate their sense of time. You can't, and you need that clinician who knows the patient and who knows RET to be able to judge that. So it's really the combination of those two that creates that composite. So I think you still have regulatory questions, but I at least answer that.
Speaker 0
I think that's actually really helpful. And maybe even before we talk a little bit about the bar for success, because you got really in the weeds on the protocol, the pivotal study, You know, a lot of that is implemented to make sure that there's no, like, expectation or rate or bias in any of this stuff. And I think it raises the natural question of just, like, when you think back to the Phase 1-2 that doesn't have that same level of blinding, like, what gives you the confidence that there isn't any, like, rate or bias embedded in some of the milestone data that you have produced?
Rachel McMinn, CEO
Yeah, it's a good question. I think what's exciting about the phase 1-2 data is that when we first started enrolling these patients and observing how they were doing, They were coming back to us. The milestones weren't actually, excuse me, prospectively kind of built into the protocol design because we didn't know what we would see. Sorry. I do have water, but I think, apologies, I'm getting over some.
Speaker 0
Cold and flu season.
Rachel McMinn, CEO
It's just not a good time.
Speaker 0
Yeah, it's all good.
Rachel McMinn, CEO
So, those participants, what we found was that over time, They, they, we were finding out that they were, they were actually performing these new and developing these, these milestones that they had never done before, or they had done only during the regression phase or prior to regression. So it's a really, sorry. So it was a really kind of spontaneous set of data that we were collecting. I know this is ridiculous.
Speaker 0
I just feel for you. Does anyone have a water? I don't have water.
Rachel McMinn, CEO
It's literally just like, give me a second. The cough drop will work, I promise.
Speaker 0
Don't worry about it.
Rachel McMinn, CEO
Okay, we're resetting. Sorry, everybody, for being human. I don't like being human.
Speaker 0
To be clear, fighting through that and being up here is, I guess, a bullish sign. We actually had an executive, I won't say, who at our ski conference maybe five or six years ago tore his ACL and then still did his fireside chat.
Rachel McMinn, CEO
There you go. You don't need your ACL to talk, but you do need your voice box to talk.
Speaker 0
I agree with that.
Rachel McMinn, CEO
But in any case, so I think what was exciting about what we saw in the phase one, too, is that despite the fact that we weren't actually going in and trying to, like, ask for these girls to, like, I wonder if she can sit up unassisted.
Speaker 0
It was being reported to you by what people were seeing.
Rachel McMinn, CEO
Exactly. Like, we'd come back and be like, oh, my gosh, look at what she can do now. She could never do that before. So it was really, really remarkable findings that we were seeing. And just over time, you know, we would see this across the population. So I think what's exciting is like that was in a setting in which it was not, you know, not all of these milestones were actually being assessed for in that type of way. And despite that, we actually saw it across the participants. So I think we're excited about that. You know, again, going back to embolden, this is a binary yes, no. Like, does she have the skill? Does she not? Not skill, but like, does she have the milestone or does she not have the milestone? So I feel like, you know, the combination of we saw it across the phase one, two, across the age range, across the disease severity. And then being able to, you know, really fully interrogate this in the pivotal study is very exciting. I think we're very optimistic.
Speaker 0
Yeah, that's great. So as it relates to how you power the trial, maybe going back to like all this background was great, but like going back to the power trial, I think you've powered it for like maybe a 30% responder rate. Is it 35%?
Rachel McMinn, CEO
Yeah, so in order to reach statistical success, now that we have the full 25 patients that are included in the efficacy data set, so there's a slight update that we just announced earlier this week, where as part of being part of our SART meetings with FDA, If you recall, initially we were targeting 20 patients. We over-enrolled. That number ended up being 25 participants. And when we had our initial statistical analysis plan, it allowed for up to 24. So we said, okay, it's up to 24. And then we thought, well, this is really silly. Like, are we really going to leave out a patient out of the efficacy data set? FDA agreed. And so we've now amended the statistical analysis plan so that it's the full 25. So when you have the full 25, the statistical threshold for success is 9 out of 25. Thirty-six percent. So that is powered against a null hypothesis rate that is obviously below that. So nothing has changed other than the denominator being slightly bigger than where it was before. But in terms of what do you need for actual success in the market, we think that number is going to need to be higher. Over 50?
Speaker 0
I don't want to put an actual percentage number. I thought biotech companies love setting quantitative specific bars.
Rachel McMinn, CEO
I know. You want to hold me to a specific number. But no, in reality, obviously, we're going to be testing all of this in market research, and I don't have the data today. I do think there's a very broad range of expectations out there from the community, and part of this is shaping this. But it's not even about, like, a percent responder. Part of this is about, you know, seeing a multi-domain, you know, breadth of response. And so one of our key secondaries is the number of developmental milestones gained. So it'll be the proportion of patients that gain one, the proportion of patients that gain two, et cetera. And we think this is really important from a differentiation perspective. Because, you know, ultimately, that's really what families are looking for. So we've definitely heard from some families that even, you know, like the smallest of gains, I, you know, I was just visiting with the head of the RSRT Foundation, which is one of the two major patient advocacy groups and, and Chelsea, who's Monica's daughter, and she's just about to turn 30 years old. And it's actually getting Hard for the family to be able to lift Chelsea and move her around. So, you know, when you think about, you know, some of the comments that we've heard. You know, for somebody like that is could, you know, if it's easier and, you know, for transfers, like even even small incremental benefits would be meaningful. You know, we've talked to families where, you know, if they could just, you know, not feed every single mouthful of dinner to them, if their girls could feed themselves a little bit, that would be a huge win. Right. So I think that, you know, the bar is reasonably low, but nonetheless, it's a one-time gene therapy, which means that, you know, families are having to make a decision where you don't get to take it back, right? Like once you take one gene therapy, you've exhausted that option. And so that's, you know, that these are the kinds of decisions that families are going to have to make.
Speaker 0
As you've thought about enrolling patients in the Pivotal study, and obviously you have some window into the types of patients that have come into the trial, I would think, in terms of their baseline capability, do you feel like the population you've enrolled gives you an opportunity to show benefit on a number of different domains, like motor or language or communication or things like that? I would imagine it's very variable patient to patient based on where their starting point is.
Rachel McMinn, CEO
Exactly. I mean, for somebody to have a gross motor function gain in some ways can be much more of a challenge because think about a girl who's not ambulatory. So she's sitting in a wheelchair. Her muscles just don't even have the kind of tone that they would need in order to be able to stand up. So for that girl who's been sitting in a wheelchair for years, for her to gain a gross motor function, it might take a couple of years. That might be a tough order for that to happen in 12 months, but maybe she will be able to feed herself with a fork, and that would be a huge outcome for her. Whereas somebody else who might be teetering on the verge of they have not very great balance, but they might be able to gain those types of gross motor milestones. I think what we can say based on the phase one, too, is every single one of our girls had a hand function gain. Some of them had multiple hand function developmental milestone gains. That's really remarkable. We hit almost all of the communication developmental milestones as well. So it was all hand function milestones were achieved. Most of the communication milestones were achieved, and about half of the gross motor milestones were achieved. And I think that just kind of speaks to the time and kind of the other things that are required in order to achieve a gross motor milestone. But yes, the more patients we have, the more ability to showcase these various milestones.
Speaker 0
In the past month, you had a number of scientific presentations, and we caught up, right, in talking about sort of the potential related to speed of onset, biodistribution, like all kind of stuff I think that addresses some of the people's questions around NGN 401 and also the competitive landscape with other retching therapies. Do you maybe want to, like, talk about some of those presentations and the context around it?
Rachel McMinn, CEO
Yeah, I would love to. I mean, one of the things that we think is really important to mention is that NGN-401 was designed with a clean piece of paper. We designed what we thought was going to be the ideal gene therapy. And so what does that mean? You know, first and foremost is if you don't transduce enough neurons in the brain, you're not going to be able to have the kind of effect that you want to have. So we ran head-to-head studies. Showing that ICV as a route of delivery was really, you know, 10 to 100 fold more effective of getting to the brain. So that was sort of point one. So we have presented that data in the past, and we're continuing to present that. And I'll mention that the only reason to bring that up is, you know, some people continue to bring up like, oh, why would you want to have an invasive procedure? But, you know, for a one-time, you know, gene therapy treatment, it makes a lot of sense. And, you know, once people better understand the procedure, the fact that it's very well tolerated and very common, and it gets to more neurons in the brain, they're like, okay, that makes sense. You know, some of the other aspects of differentiation, one is really the full-length gene. And, you know, there's been some noise and misconception out there about, you know, single-stranded vectors being, like, too slow and having a slow onset of action. And we're like, this is just silly. So we ran the experiment and showed that by the very first time point that you get transduction and expression of transgene as early as day seven. And what we reminded people is that a single-stranded vector accommodates the full-length gene. Like, you would never go in and intentionally, like, lop off two-thirds of the gene if you didn't need to. So, you know, the full-length gene fits comfortably into a single-stranded vector, and we show that there's no downside. It is very rapid and supports the rapid onset of action that we see clinically. So that was very well received. And then finally, there's been a misconception that there's a microRNA-based technology that was somehow able to express differentially in cells that lack MeCP2, and we showed in our study, very plain and simple, that that's just not the way these technologies work, and that they both, you know, contain and dampen transgene expression to avoid overexpression toxicity, But there really isn't one that is out there that is, you know, kind of safer or more selective than another. And again, this is something that clinicians really appreciated having the science behind it to help make informed treatment decisions around, you know, future gene therapy. So I think, you know, all in all, what we like about the differentiation is we have that full-length gene, so we're getting the maximal. Like, we're not – you're not taking any risk of, like, what if a smaller gene doesn't really – isn't durable, isn't stable. We're getting to as many neurons as possible, and we have a regulation technology that works as intended to be able to control overexpression toxicity.
Speaker 0
Yep. Yep. Okay. Great. Between now and the top line, will we get additional data from the Phase 1-2?
Rachel McMinn, CEO
So we are very focused, as I mentioned, on the BLA and Emboldened. And, you know, with data coming out in the second half of 27, the team is laser-focused on that. So we do not plan to release Phase 1 data prior to Emboldened. The long-term follow-up of the Phase 1-2 is very important. We have a publication strategy around it, but when we think about putting that BLA together, we have 12 to 30 months of data already in the public domain for people to be able to interrogate and be able to make their investment decisions based on that ahead of the pivotal, but there's no plans to release additional data. Yeah.
Speaker 0
Okay. Makes sense. Do you want to maybe briefly talk about the commercial market? How many patients do you feel like are out there? Who do you think are the likely early adopters of something like this if it did get approved?
Rachel McMinn, CEO
Yeah, so work that we are kicking off and continuing, and we'll have a lot more to say about this next year with Christy's team continuing to build out. But one of the things that I heard that I thought was pretty remarkable was that initially when Debut was launched, so Debut is approved for Rett syndrome. It's the only drug that's approved for Rett syndrome from Acadia. They had about 4,000 patients in the claims database, and now it's over 6,000. Over a relatively short period of time. I mean, that's really remarkable. Like, so congrats to them. And like, they've done a huge amount of lifting and I think helping to shape and, you know, raise disease awareness for all of us. So I think that's a fantastic market to launch into where the numbers of patients are actually like kind of increasing in the system. So I would just put that out there. From a reimbursement perspective, they've also done a lot of work in helping to educate payers. So when we did our initial preliminary market research, you know, people did not, the payers are not pushing back at all. Like, they know what the CGI is, and they're like, wow, you have functional milestones? That's amazing. So that's on top of something that they know already very well from Debut, which is, you know, they prefer the CGI much more than the RSPQ. So I think, again, setting the table and helping to set the stage for future products like ours coming into market, and from a pricing perspective as well, the price of Debut is actually quite high. And when you look at the numbers and think through a couple of years of Debut is already at a typical gene therapy price point. And that's with a product profile that we think is not going to be in the same zip code as the kind of benefits that we're able to see with the disease-modifying therapy. So I think there's a really good atmosphere, kind of landscape that we're launching into. All of the work on treatment centers, this is something that, you know, stay tuned on that. We're doing work on that because ultimately that's going to provide the, you know, the numbers onto which we're, you know, you guys are going to start modeling, you know, numbers of patients per treatment center and, you know, what that looks like. So stay tuned on that. But this is work that is ongoing and to come in 27. Great.
Speaker 0
We only have 30 seconds left. Anything else you'd like to add? Maybe just touch upon Cash Runway.
Rachel McMinn, CEO
Yeah, so ended the quarter with about $360 million in cash and equivalents, and that takes us into the first quarter of 29. So we are well-funded to really get through a lot of these key inflection points for the company. Great. Best of luck and feel better.